Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients

被引：4
|
作者：
Funk, R. K. [1 ]
Davis, B. J. [1 ]
Mynderse, L. A. [1 ]
Wilson, T. M. [1 ]
Deufel, C. L. [1 ]
Furutani, K. M. [1 ]
Pisansky, T. M. [1 ]
Haddock, M. G. [1 ]
Choo, C. R. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2535
引用
收藏
页码：E213 / E214
页数：2
相关论文
共 50 条
  • [21] Outcomes Following I-125 Prostate Brachytherapy as Monotherapy
    Ohashi, T.
    Yorozu, A.
    Saito, S.
    Momma, T.
    Toya, K.
    Nishiyama, T.
    Yamashita, S.
    Shiraishi, Y.
    Shigematsu, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S344 - S345
  • [22] Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review
    Rodrigues, George
    Yao, Xiaomei
    Loblaw, D. Andrew
    Brundage, Michael
    Chin, Joseph L.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2013, 7 (11-12): : 463 - 470
  • [23] LOW-DOSE-RATE BRACHYTHERAPY FOR LOW- AND INTERMEDIATE-RISK PROSTATE CANCER: A DOSE-RESPONSE ANALYSIS FOR 3392 CONSECUTIVE 125-IODINE MONOTHERAPY PATIENTS
    Morris, W. James
    Spadinger, Ingrid
    Halperin, Ross
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S28 - S28
  • [24] NATURAL HISTORY OF CLINICALLY STAGED LOW- AND INTERMEDIATE-RISK PROSTATE CANCER TREATED WITH MONOTHERAPEUTIC PERMANENT INTERSTITIAL BRACHYTHERAPY
    Taira, Al V.
    Merrick, Gregory S.
    Galbreath, Robert W.
    Wallner, Kent E.
    Butler, Wayne M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (02): : 349 - 354
  • [25] Two-step transurethral surgery of the prostate and permanent implant brachytherapy for patients with lower urinary tract symptoms and low- to intermediate-risk prostate cancer
    Ivanowicz, Allie N.
    Wakeman, Carolyn M.
    Hubbard, Ryan T.
    DeVoe, William B.
    Haake, Michael R.
    Teigland, Chris M.
    BRACHYTHERAPY, 2012, 11 (06) : 483 - 488
  • [26] Active surveillance in low- and intermediate-risk prostate cancer
    Cerbone, Linda
    Regine, Giovanni
    Calabro, Fabio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 582 - 583
  • [27] Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer
    Aluwini, Shafak
    Busser, Wendy M. H.
    Alemayehu, Wendimagegn Ghidey
    Boormans, Joost L.
    Kirkels, Wim J.
    Jansen, Peter P.
    Praag, John O.
    Bangma, Chris H.
    Kolkman-Deurloo, Inger-Karine K.
    RADIOTHERAPY AND ONCOLOGY, 2015, 117 (02) : 252 - 257
  • [28] Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer
    Gestaut, Matthew M.
    Cai, Wendi
    Vyas, Shilpa
    Patel, Belur J.
    Hasan, Salman A.
    MunozMaldonado, Yolanda
    Deb, Niloyjyoti
    Swanson, Gregory
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 101 - 107
  • [29] Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer
    Hinnen, Karel A.
    van Vulpen, Marco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (01) : 115 - 123
  • [30] I-125 LDR Brachytherapy in Patients with Low-risk Prostate Cancer - a retrospective Analysis of Patients
    Fels, F.
    Okonkwo, E.
    Schadt, T.
    Laschke, S.
    Loevey, G.
    Lansing, D.
    Grossmann, J. G.
    Freund, U.
    Steurer, R.
    Momm, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S87 - S87
12345